Previous 10 | Next 10 |
2023-12-14 15:01:02 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M Alector achieves target enrollment for Phase 3 dementia study Seeking Alpha’...
2023-12-14 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Ocular Therape...
SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The e...
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 1...
Alector Inc. (ALEC) is expected to report $-0.65 for Q3 2023
2023-11-07 17:25:05 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector achieves target enrollment for Phase 3 dementia study Alector slips as Goldman Sachs starts at Sell on risk to lead programs Seeking Alpha’s Quan...
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’s disease in Q3 2023, data readout expecte...
2023-10-27 13:59:06 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript Alector slips as Goldman Sachs starts at Sell on risk to lead programs Alector completes enrollments in mi...
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRON...
2023-10-26 09:49:41 ET Summary INmune Bio is a phase 2 stage biotech company focusing on Alzheimer's and other diseases with its lead asset, XPro, and its endogenous NK cell activator, INKmune. INmune's XPro has shown promising results in stabilizing Alzheimer's disease and improv...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...